Moreover, increased FGF-2 immunoreactivity significantly correlates with an increased risk of chronic lymphocytic leukemia (CLL) and, at the same time, with a reduced susceptibility to apoptosis. The gene discussed is FGF2; the disease is B-cell chronic lymphocytic leukemia.